Source-grounded facts extracted from Transcode Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not”
Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not”
Transcode Therapeutics, Inc. entered into Standby Equity Purchase Agreement with YA II PN, LTD valued at $14 million (effective 2026-04-06).
“On April 6, 2026 , TransCode Therapeutics, Inc., a Delaware corporation, (the “Company,” “we,” or “our”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited partnership (“Yorkville”), pursuant to which the Company has the right to sell to Yorkville up to $14 million of shares of the Company’s common stock”
Transcode Therapeutics, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2026-03-02).
“On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware”
Transcode Therapeutics, Inc.: Amended Section 6.1.1 of the Certificate of Designation to clarify conversion limits and removed the holder's right to convert Preferred Stock into Common Stock upon delisting from Nasdaq (effective 2025-10-27).
“The Amended and Restated Certificate of Designation amended Section 6.1.1 of the Prior Certificate to clarify that for as long as the Purchase Agreement remains in effect and for as long as any shares of Preferred Stock remain outstanding, prior to receipt by the Company of the stockholders’ approval of the conversion of the applicable series of Preferred Stock into shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), in accordance with the listing rules of the Nasdaq Stock Market, as set forth in the Purchase Agreement, the Company shall not issue pursuant to the Purchase Agreement and Section 6.1.1 of the Amended and Restated Certificate of Designation more than an aggregate of 19.9% of the Common Stock outstanding as of October 8, 2025. In addition, the Amended and Restated Certificate of Designation removed the ability of a holder of Preferred Stock to convert, at the option of such holder, the Preferred Stock into Common Stock in the event of a delis”
Transcode Therapeutics, Inc.: Filed Certificate of Designation for Series A and Series B Preferred Stock, establishing their rights, preferences, and limitations (effective 2025-10-08).
“On October 8, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock and Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Acquisition and the Investment referenced in Item 1.01 above.”
Transcode Therapeutics, Inc. completed an acquisition involving DEFJ, LLC (closed 2025-10-08).
“On October 8, 2025, the Company completed its acquisition of DEFJ.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.